MC1568, also known as MC-1568, is a small molecule inhibitor of histone deacetylase 2 (HDAC2), which is an enzyme involved in the regulation of gene expression through chromatin modification. It was first discovered in 2007 and has since been studied for its potential as a treatment for various diseases, including cancer and neurodegenerative disorders.
Chemical name:
The chemical name for MC1568 is N-(6-chloro-2-methoxy-9-acridinyl)-1-naphthalenecarboxamide.
Molecular formula:
The molecular formula of MC1568 is C25H17ClN2O3.
Formula weight:
The formula weight of MC1568 is 432.86 g/mol.
CAS No:
The CAS number of MC1568 is 852475-26-4.
Top ten keywords from Google and Synonyms:
Synonyms:
Health benefits of this product:
MC1568 has been primarily developed for the treatment of cancer and neurodegenerative disorders. As an HDAC2 inhibitor, it is thought to regulate gene expression by promoting acetylation of histones, leading to changes in chromatin structure and gene transcription.
Potential effects:
Some potential effects of MC1568 include:
Product mechanism:
MC1568 works by inhibiting HDAC2, which is an enzyme involved in the regulation of gene expression through chromatin modification. By inhibiting HDAC2, MC1568 can promote acetylation of histones, leading to changes in chromatin structure and gene transcription.
Safety:
MC1568 has been tested in preclinical and clinical studies for its safety profile. The drug has been found to have acceptable toxicity and has not shown any significant adverse effects on normal tissues or organs. However, as with any medication, there are some risks associated with its use. Patients should inform their healthcare provider of any pre-existing medical conditions or medications they are taking before starting treatment with MC1568.
Side effects:
MC1568 can cause several side effects in some patients. These can include:
Dosing information:
The optimal dosing regimen of MC1568 has not yet been established and further research is needed to determine the most effective dose. In preclinical studies, doses ranged from 5 to 20 mg/kg. In clinical trials, doses ranged from 10 to 25 mg once daily. The drug is typically administered orally.
Conclusion:
MC1568 is a small molecule inhibitor of HDAC2 that has shown potential as a treatment for various diseases, including cancer and neurodegenerative disorders. By inhibiting HDAC2, MC1568 may regulate gene expression by promoting acetylation of histones, leading to changes in chromatin structure and gene transcription. The drug has undergone several preclinical and clinical trials and has been found to have an acceptable safety profile. However, as with any medication, there are some risks associated with its use. Further research is needed to determine the optimal dosing regimen and efficacy of MC1568 in treating various diseases.
